A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of GS-5806 in Hematopoietic Cell Transplant (HCT) Recipients With Respiratory Syncytial Virus (RSV) Infection of the Upper Respiratory Tract
Phase of Trial: Phase II
Latest Information Update: 20 Mar 2019
Price : $35 *
At a glance
- Drugs Presatovir (Primary)
- Indications Respiratory syncytial virus infections
- Focus Therapeutic Use
- Sponsors Gilead Sciences
- 17 Mar 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.
- 07 Oct 2018 Results of a combined resistance analyses from this and three other phase 2b studies, presented at the IDWeek 2018.
- 13 Oct 2017 Status changed from active, no longer recruiting to completed.